Business Wire

CGTN: China Eyes Good Start to 14th Five-Year Plan Period Ahead of Spring Festival

Share

A New Year is a new beginning. With this year's Spring Festival, or the Chinese Lunar New Year, just around the corner, China is also well prepared for the beginning of the 14th Five-Year Plan (FYP) period (2021-2025) and the centenary of the Communist Party of China (CPC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005816/en/

Ahead of the Spring Festival, Chinese President Xi Jinping extended Spring Festival greetings to all Chinese Wednesday at a reception in Beijing and called for a good start in boosting the country's development during the 14th FYP period so as to celebrate the Party's centenary with outstanding achievements.

Ready for a new journey in the 14th FYP period

Facts have once again proven that the system of socialism with Chinese characteristics has incomparable vitality and creativity, Xi said.

As long as the entire Party and the Chinese people of all ethnic groups rally closely around the CPC Central Committee, there is no difficulty that cannot be overcome, he said.

The year 2021 is crucial to China as the nation is set to achieve its first centenary goal within the set time frame – to complete the building of a moderately prosperous society in all respects – and begin the work towards the second goal, to fully build a modern socialist country.

Stressing the goal of promoting high-quality development, President Xi highlighted the importance of the country's new stage of development, the implementation of this new vision of development, and the construction of a new pattern of development in 2021.

To meet the people's ever-growing needs for a better life, efforts are needed in deepening supply-side structural reform while taking reform and innovation as the fundamental driving force, the Chinese president said.

Consolidating and expanding achievements in epidemic containment and economic and social development are necessary, he added.

Great achievements in 2020 as solid foundation

President Xi also looked back on the past year which he described as "extraordinary" in his New Year speech.

Xi hailed what has achieved in COVID-19 prevention, poverty alleviation, flood prevention, rescue and relief work, and reform and opening-up, and highlighted the country's progress in technology, economy and the Belt and Road construction.

China is one of the most resilient economies amid the ravaging pandemic and global economic slump. The country was among the first to have put the virus under control, to have resumed work and production and to have realized economic stability and recovery, which not only made it the first major economy in the world to register positive growth in 2020 but also brought confidence and hope to others in the world.

On November 23, as southwest China's Guizhou Province cleared all the names on its poverty list, China announced the eradication of absolute poverty and regional poverty.

At a symposium on securing a decisive victory in poverty alleviation in March, President Xi said lifting all rural residents living below the poverty line out of poverty by 2020 is a solemn promise made by the CPC Central Committee and it must be fulfilled on time.

Original article: here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye